10-Q: STAAR Surgical Reports Q2 Loss Amid China Slowdown

STAAR Surgical Company reported a significant net loss and revenue decline in Q2 2025, primarily driven by reduced sales in China, while announcing a definitive merger agreement with Alcon for $28.00 per share.

Summary

• Net sales for the six months ended June 27, 2025, decreased by 50.7% to $86.909 million, down from $176.361 million in the prior year period.
• The company reported a net loss of $71.023 million for the six months ended June 27, 2025, a significant decline from a net income of $4.040 million in the same period of 2024.
• Gross profit for the six months ended June 27, 2025, decreased by 56.4% to $60.804 million, with gross margin falling to 70.0% from 79.1%.
• Operating income shifted to a loss of $87.365 million for the six months ended June 27, 2025, compared to an operating income of $9.617 million in the prior year.
• Restructuring, impairment, and related charges totaled $27.912 million for the six months ended June 27, 2025, including $12.453 million for severance and workforce reduction, and $7.759 million for fixed asset impairment.
• Cash and cash equivalents increased to $167.131 million as of June 27, 2025, from $144.159 million at December 27, 2024, primarily due to proceeds from investment maturities.
• A share repurchase program of up to $30 million was authorized in May 2025, with $4.479 million in shares repurchased by June 27, 2025, and an additional $1.982 million repurchased by August 1, 2025.
• The company entered into a definitive merger agreement with Alcon Research, LLC on August 4, 2025, to be acquired for $28.00 per share in cash.

Sentiment

Score: 3

Explanation: The company's operational performance for the period was significantly negative, marked by substantial revenue decline and net losses, primarily due to challenges in the China market and significant restructuring charges. While the announced merger provides a potential positive exit for shareholders, the underlying business results are very weak.

Positives

• Cash and cash equivalents increased by $22.972 million, reaching $167.131 million, providing strong liquidity.
• Net cash provided by investing activities was $60.471 million for the six months ended June 27, 2025, primarily from proceeds from maturity of investments available for sale.
• The company is actively ramping up production capabilities in Switzerland to diversify manufacturing capacity and reduce tariff risk.
• The restructuring effort, including leadership realignment and cost reductions, was substantially completed as of June 27, 2025, aiming for sustainable growth.
• Sales in the EMEA region increased by 14% with ICL unit growth of 9%, and Americas region sales increased by 10% with ICL unit growth of 6% for the six months ended June 27, 2025.

Negatives

• Net sales decreased significantly by 50.7% for the six months ended June 27, 2025, primarily due to a 66% decrease in the Asia Pacific (APAC) region, driven by a substantial decline in China sales.
• The company reported a net loss of $71.023 million for the six months ended June 27, 2025, a sharp reversal from a net income of $4.040 million in the prior year period.
• Gross profit margin decreased to 70.0% from 79.1% for the six months ended June 27, 2025, due to higher manufacturing costs per unit from lower production volume and increased excess/obsolete inventory reserves.
• Operating income turned into a significant loss of $87.365 million for the six months ended June 27, 2025.
• The company incurred $27.912 million in restructuring, impairment, and related charges for the six months ended June 27, 2025, reflecting significant operational adjustments and asset write-downs.

Risks

• The proposed acquisition by Alcon could adversely impact business by impairing the ability to attract, retain, and motivate employees, diverting significant management time and resources, and creating difficulties in maintaining relationships with customers, suppliers, and partners.
• The completion of the merger is subject to various closing conditions, including stockholder approval and regulatory approvals in specified jurisdictions (e.g., Hart-Scott-Rodino, China, Japan), which may not be satisfied on a timely basis or at all.
• Failure to consummate the merger could result in negative publicity, a negative impression among customers and the investment community, and continued business disruptions.
• The company may be required to pay Alcon a termination fee of up to $43.4 million if the merger agreement is terminated under specified circumstances.
• Litigation relating to the merger may be filed against the company or its directors/officers, which could delay or prevent the merger's completion and incur significant costs.
• The company's largest investor beneficially owns approximately 27% of outstanding shares, and their vote against the merger agreement could materially adversely affect the ability to satisfy the stockholder approval condition.
• Prolonged slowdown or disruption in China and the status of trade tariffs between the United States and China pose ongoing financial exposure risks.

Future Outlook

The company expects China revenue to normalize in the second half of fiscal 2025 as distributors increase ICL purchases to meet forecasted demand. The shift to consignment agreements in China is anticipated to lead to more frequent, smaller purchases aligned with actual procedural volumes, reducing distributor inventory buildup risk. The company is also rapidly ramping up Swiss production capabilities to supplement U.S. manufacturing and provide optionality under multiple tariff scenarios. The proposed merger with Alcon is expected to close subject to stockholder and regulatory approvals.

Management Comments

• "We expect our China revenue will normalize in the second half of fiscal 2025, as our distributors increase their purchases of ICLs to meet forecasted demand."
• "While the tariff situation is evolving, we believe that these efforts to increase the amount of ICLs in China reduce the Company’s tariff risk in China in the near-term."
• "We are rapidly ramping up our production capabilities in Switzerland to supplement our manufacturing capacity in the United States to provide optionality under multiple tariff scenarios."
• "The restructuring effort was substantially completed as of June 27, 2025."

Industry Context

The ophthalmic surgical market, particularly for refractive surgery, is dynamic and influenced by macroeconomic conditions and regional demand. STAAR Surgical's significant sales decline in China reflects specific challenges in that key market, including distributor inventory levels and evolving tariff situations. The company's strategic shift to consignment models and diversified manufacturing aims to adapt to these regional complexities. The proposed acquisition by Alcon, a major player in eye care, indicates a potential consolidation trend or a strategic move by Alcon to acquire a leading phakic IOL technology, potentially signaling a belief in the long-term value of STAAR's core product despite recent headwinds.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in various legal proceedings and other matters arising in the normal course of business, including contractual rights, employment matters, and product liability claims.
• New claims or unexpected results of existing claims could lead to significant financial harm, despite the company's belief that known claims are unlikely to have a material adverse effect.
• Litigation relating to the proposed merger with Alcon may be filed against the company or its directors/officers, seeking damages or injunctions, which could delay or prevent the merger.

Stakeholder Impact

• Shareholders: Face significant operational losses but have a potential cash exit at $28.00 per share through the Alcon merger, subject to closing conditions and risks.
• Employees: Affected by leadership realignment and workforce reductions, with severance costs incurred. Uncertainty related to the merger could impact attraction, retention, and motivation.
• Customers and Suppliers: May experience difficulties in maintaining relationships and potential delays or deferments of business decisions due to merger uncertainty.
• Creditors: Financial health impacted by significant losses, but liquidity remains strong with increased cash and cash equivalents.

Next Steps

• Stockholders will vote on the adoption of the Merger Agreement with Alcon at a meeting to be announced.
• The company will continue to pursue regulatory approvals for the Alcon merger in specified jurisdictions, including China and Japan.
• The company expects China sales to return to normalized levels beginning in the third quarter of 2025.
• Continued ramp-up of production capabilities in Switzerland to supplement U.S. manufacturing capacity.

Key Dates

Recommendation

The company's operational performance is significantly deteriorating, marked by substantial revenue decline and net losses, particularly due to challenges in the China market. However, the announced merger agreement with Alcon at $28.00 per share provides a clear, fixed exit price for shareholders, which could be seen as a favorable outcome given the current operational struggles. The recommendation is 'Hold' because the stock price is likely to trade close to the acquisition price, with limited upside potential unless a higher bid emerges, and downside risk if the merger fails to close. Investors should hold to realize the merger consideration, while new investors might find better opportunities elsewhere given the operational headwinds if the merger doesn't materialize.

Keywords

Ophthalmic Surgical, Implantable Collamer Lenses, ICL, Refractive Surgery, Medical Devices, Alcon Merger, SEC Filing, Quarterly Report, Financial Performance, China Market